Body weight changes after adjuvant chemotherapy of patients with breast cancer: results of a Mexican cohort study

Abstract

Weight gain is observed in breast cancer patients receiving chemotherapy and is a well-known complication. Several factors that contributing to weight gain have been identified. However, there is a lack of information about factors associated with weight changes following adjuvant chemotherapy. A retrospective cohort of 200 pre- and post-menopausal Mexican patients treated for breast cancer was made. Anthropometric variables were measured before/after treatment. Biomarkers, cellular differentiation and chemotherapy were similar between groups. Weight gain occurred in 85.6% of pre-menopausal and 72.6% of post-menopausal women (p = .03). At the end of chemotherapy, weight and body mass index (BMI) did not differ significantly between pre-menopausal (69.3 ± 12.6 kg; 26.6 ± 4.8 kg/m ) and post-menopausal women (69.5 ± 10.9 kg; 27.3 ± 4.4 kg/m ) (p = .91 and 0.34). Dexamethasone doses were higher in pre-menopausal (85.7 ± 39.1 g) than post-menopausal patients (79.2 ± 22.5 g; p = .13). Weight loss was observed in 9.2% of pre-menopausal and 20.2% of post-menopausal patients (p = .04). A multivariate analysis revealed that age (OR = 2.7; 95% CI = 1.26-5.79; p = .01), menopausal status (OR = 2.29; 95% CI = 1.09-4.80; p = .03), dexamethasone dosage (OR = 2.1; 95% CI = 1.04-4.23; p = .03) and daily caloric intake (OR = 2.3; 95% CI = 1.12-5.10; p = .02) were independent variables that inducted weight gain. Pre- and post-menopausal women gained weight, but more pre-menopausal patients showed gain. An effort should be made to administer lower steroid doses to reduce weight gain.

Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane

“…25 kg/m 2 and a BMI < 25 kg/m 2 . 12 In a study of weight changes after diagnosis and the prognosis among women with earlystage breast cancer, of the women with a BMI < 30 kg/m 2 , 38.9% had gained ! 5% of their body weight compared with 25.9% who had gained the same amount among women with a BMI of !…”

Clinical Predictors of Weight Gain in Early Breast Cancer Survivors

“…Along with improved disease survival, advances in breast treatment have brought with them a considerable degree of adverse effects. Most of breast cancer survivors have been found to be overweight or obese (Ewertz et al, 2012;Imayama et al, 2013;Ortiz-Mendoza, de-la-Fuente-Vera, & Pérez-Chávez, 2014), especially early-stage breast cancer (EBC) survivors with significant weight gain after adjuvant treatment (Arce-Salinas et al, 2014;Vargas-Meza et al, 2017), hormone therapy (Kai Lorizio et al, 2012)..The relationship between breast cancer recurrence and weight change was first investigated by Abe et al (Abe, Kumagai, Kimura, Hirosaki, & Nakamura, 1976); and chemotherapy (Jung, Kim, & Chung, 2020;Schvartsman et al, 2017; was associated with weight gain, especially when cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regiment were more obvious ( Jung et al, 2020;Schvartsman et al, 2017;. The problem of weight gain has been around for a long time and it is still found that almost two years after the diagnosis, the weight has increased by 1.9 to 5.1 kg (Makari-Judson, Braun, Jerry, & Mertens, 2014;Reddy et al, 2013), which shows that this problem still exists and is serious.…”

Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer

“…In many studies, significant weight gain was observed during chemotherapy in women with breast cancer [56789]. There has been increasing evidence that weight gain during chemotherapy is associated with increased recurrence risk and decreased survival [21011].…”